2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
14
Carcinoid Tumor
5
Gastro-enteropancreatic neuroendocrine tumor
4
Acromegaly
4
Serotonin Syndrome
2
Pituitary Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Hepatocellular
2
Prostatic Neoplasms
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Paraganglioma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Intestinal Obstruction
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gigantism
1
Gastrointestinal Neoplasms
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Carcinoid Heart Disease
1
Adenoma, Islet Cell
1
Interventions
lanreotide
1
Hyperthermic Intraperitoneal Chemotherapy
1
Ethanol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Flushing
×
lanreotide
×
Clear all
NCT00774930
2022-10-14
ELECT
Ipsen
Phase 3
Completed
115 enrolled
17 charts